/wp-content/uploads/logo-300x63.png00Jake Robison/wp-content/uploads/logo-300x63.pngJake Robison2024-09-04 05:29:062024-09-04 05:33:49Synthekine Granted U.S. FDA Fast Track Designation for CD19 CAR-T and Orthogonal IL-2 Investigational Therapy, SYNCAR-001 + STK-009, for the Treatment of Lupus Without Lymphodepletion
/wp-content/uploads/logo-300x63.png00eallison/wp-content/uploads/logo-300x63.pngeallison2024-03-20 12:30:442024-03-25 14:51:17Synthekine Announces U.S. FDA Clearance of IND Application for CD19 CAR-T and Orthogonal IL-2 Combination Therapy, SYNCAR-001 + STK-009, for Treatment of Lupus Without Lymphodepletion
/wp-content/uploads/logo-300x63.png00eallison/wp-content/uploads/logo-300x63.pngeallison2024-03-06 14:29:552024-03-06 14:58:26Synthekine Announces Presentation of Initial Results from Phase 1a/1b Clinical Trial of STK-012 at AACR 2024 Annual Meeting
/wp-content/uploads/logo-300x63.png00eallison/wp-content/uploads/logo-300x63.pngeallison2024-01-25 17:16:412024-03-06 14:41:33Synthekine Announces Strategic Collaboration with Sanofi to Develop Selective IL-10 Agonists for Treatment of Inflammatory Diseases
/wp-content/uploads/logo-300x63.png00David Anderson/wp-content/uploads/logo-300x63.pngDavid Anderson2023-07-26 13:50:052023-07-26 13:51:07Synthekine Doses First Patient in Phase 1 Clinical Trial of Orthogonal IL-2 and CD19 CAR-T Combination Therapy, STK-009 + SYNCAR-001, for Treatment of CD19+ Hematologic Malignancies
/wp-content/uploads/logo-300x63.png00David Anderson/wp-content/uploads/logo-300x63.pngDavid Anderson2023-04-11 17:22:132023-04-11 17:22:13Synthekine Announces Presentations at AACR 2023 Annual Meeting Showcasing Next Series of Oncology Programs
